Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.21 USD | -5.85% | -8.31% | -40.12% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.12% | 225M | C | ||
+28.66% | 49.18B | B- | ||
+0.96% | 42.11B | B | ||
+50.47% | 40.37B | A | ||
-5.26% | 28.85B | C | ||
+13.38% | 26.09B | B- | ||
-22.60% | 18.71B | B | ||
+8.07% | 13.26B | B+ | ||
+32.17% | 12.32B | C+ | ||
-0.37% | 11.99B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- RCEL Stock
- Ratings AVITA Medical, Inc.